Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and cytokine correlates in diabetic macular oedema
ACTRN12618000079246Phase 4Not yet recruiting
- Sponsor
- Centre for Eye Research Australia
- Start
- Feb 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Centre for Eye Research Australia. Primary endpoint: Correlation of aqueous and serum cytokines with change in best-corrected visual acuity. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12618000079246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000079246.